基本信息
-
公司全称Zenas BioPharma （USA） LLC
-
类型生物制药商
-
产业领域药品研发/制造、生物药
-
公司人数15~50人
-
地址
-
联系电话
-
邮箱IR@zenasbio.com
-
成立时间2021-03-21
投融资
-
2024-09-13上市2.25亿美元未透露
-
2024-05-07C轮2亿美元NEA VenturesSuperstring CapitalFairmountDelos CapitalLongitude CapitalWellington ManagementEnavate SciencesPivotal bioVenture PartnersArrowMark PartnersSR OneFederated Hermes Kaufmann Funds维梧资本Rock Springs CapitalNorwest Venture PartnersQuan Venture Fund
-
2024-05-07C轮2亿美元SR OneNew Enterprise AssociateNorwest Venture PartnersDelos CapitalEnavate SciencesLongitude CapitalFederated Hermes Kaufmann FundsArrowMark PartnersFairmountWellington ManagementRock Springs CapitalPivotal bioVenture Partners维梧资本Quan Venture FundSuperstring Capital
-
2022-11-08B轮1.18亿美元Enavate SciencesPerceptive AdvisorsXencorQuan Venture FundTellus BioVenturesWellington ManagementFairmountSuperstring CapitalPivotal bioVenture PartnersAgent CapitalRock Springs Capital维梧资本Longitude Capital
-
2021-03-23未公开未透露Quan CapitalTellus BioVenturesWellington Management毓承资本
-
2021-03-23未透露未透露毓承资本Wellington Management泉创资本Tellus BioVentures
- 加载更多
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司，开发工程化单体 IgA 中性粒细胞接合器，以释放中性粒细胞对癌症的肿瘤杀伤能力，以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心（荷兰乌得勒支）进行的开创性工作，并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息